“The global pharmaceutical drug delivery market is projected to reach USD 2546.0 billion by 2029 from USD 1949.4 billion in 2024 at a CAGR of 5.5% during the forecast period.”
The global upsurge in prevalence of chronic disease, growth in geriatric populations, ongoing investments in pharmaceutical R&D, rising technological advancements and new product launches by key players are anticipated to propel the pharmaceutical drug delivery market growth during the forecast period. However, high development cost and risk of needlestick injuries become barriers to growth of pharmaceutical drug delivery products among healthcare providers and patients. Additionally, increasing pricing pressure by government bodies can pose a significant challenge to market players.
To know about the assumptions considered for the study download the pdf brochure
Some of the prominent players operating in the market include Johnson & Johnson services, inc (US) , Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US) , Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim International gmbh (Germany) and AstraZeneca. (UK).
Johnson & Johnson Services,Inc (US)
Johnson & Johnson Services inc is on of the largest players in the pharmaceutical drug delivery market. The company’s product portfolio includes a wide range of pharmaceutical drug delivery products that is focused on major therapeutic areas through which it caters to the demands of various end users.The company is strongly focusing on product innovation and R&D activities. In 2023 the annual R&D expenditure was around USD 15 million which accounts for 17.7% of overall revenue. Moreover , it has a strong presence across North America, Europe, the Asia Pacific, and Africa. In order to ensure its future growth, the company adopted strategies such as partnerships, agreements, and mergers & acquisitions to strengthen its product portfolio and customer base and expand its presence across various regions.
Novartis AG (Switzerland)
Novartis AG is leading player in the the pharmaceutical drug delivery market due to its significant presence across geographies. It has a robust portfolio of pharmaceutical drug delivery products. The company has strong brand recognition and offers a robust product portfolio in various therapeutic areas, namely, Cardiovascular, renal and metabolic, Immunology, Neuroscience and Oncology. The company has put maximum effort into its selected growth fields and prioritizes businesses for resource allocation. Novartis has also strengthened its business through partnerships, collaborations and agreements to strengthen its business operations.
Related Reports:
Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE